Unloxcyt: Dosage Form, Projected Sales, NCE-1 Date | Cosibelimab-Ipdl

Unloxcyt

Unloxcyt is an IV anti–PD-L1 antibody for adults with advanced or metastatic cutaneous squamous cell carcinoma who are not surgical or radiation candidates. It helps the immune system fight cancer by blocking PD-L1, with a documented response in nearly half of patients.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Cosibelimab-Ipdl
Innovator :

CHECKPOINT THERAPEUTICS INC
Approval Date :

13-Dec-24
Data Exclusivity Expiry :

13-Dec-28
Market Exclusivity Expiry :

13-Dec-36
Dosage Form :

Injection
Strength :

300MG/5ML(60MG/ML)
Therapeutic Category :

Anticancer
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

36
2026 :

74
2027 :

159
2028 :

256
2029 :

402
2030 :

543
2031 :

707

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Unloxcyt

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?